Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Next Step In Global Convergence: FDA Looks To Make IMDRF Software Guidance Its Own

Executive Summary

The US agency issued a draft guidance on clinical evaluation considerations for "software as a medical device." But FDA did not write the guidance internally. Instead it is an International Medical Device Regulators Forum document that was put together collaboratively by regulatory officials from across the globe. This is the first time FDA is attempting to wholesale adopt an IMDRF guidance document as its own.

You may also be interested in...



Hiring Plans Are Central To US FDA's Digital Health Plan

Hiring experts in artificial intelligence, cloud computing, cybersecurity and related fields is a central part of US FDA's recently announced "Digital Health Innovation Action Plan." The goal of the expanded team will be to make better regulatory decisions, issue new guidances and initiate a "pre-certification" pilot program for software.

Get 'HIP'AA To Digital Medtech Law: More Than Just FDA To Worry About

The digital medtech sector is growing fast. As new companies enter the space, they are going to face oversight from a slew of government agencies and statutes. While FDA is an important focus for medtech, patient privacy and cybersecurity challenges for digital products raise other, significant compliance challenges. Medtech Insight discussed the range of hurdles the digital medtech industry faces with attorneys from Akin Gump.

US FDA Plan For Adopting International Software Guideline Draws Industry Concern

The US agency was hoping to boost regulatory harmonization with the wholesale adoption of an international guideline on standalone medical device software, but medtech companies are worried that the guideline does not link up with US legislation and requirements.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT103967

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel